215530-59-9 Usage
Description
[1,2,4]Triazolo[1,5-b]pyridazine, 6-chloro-2-(1,1-dimethylethyl)is a heterocyclic chemical compound with the molecular formula C10H10ClN5. It features a triazolo pyridazine ring system and a chlorine atom, with a tert-butyl group substitution on the carbon atom of the pyridazine ring. [1,2,4]Triazolo[1,5-b]pyridazine, 6-chloro-2-(1,1-dimethylethyl)may serve as a building block in the synthesis of various drug molecules, particularly in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
[1,2,4]Triazolo[1,5-b]pyridazine, 6-chloro-2-(1,1-dimethylethyl)is used as a chemical intermediate for the synthesis of drug molecules. Its unique structure and functional groups make it a promising candidate for the development of new pharmaceuticals with potential therapeutic applications.
It is important to handle [1,2,4]Triazolo[1,5-b]pyridazine, 6-chloro-2-(1,1-dimethylethyl)with care and follow proper safety procedures due to its potentially hazardous nature.
Check Digit Verification of cas no
The CAS Registry Mumber 215530-59-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,5,5,3 and 0 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 215530-59:
(8*2)+(7*1)+(6*5)+(5*5)+(4*3)+(3*0)+(2*5)+(1*9)=109
109 % 10 = 9
So 215530-59-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H11ClN4/c1-9(2,3)8-11-7-5-4-6(10)12-14(7)13-8/h4-5H,1-3H3
215530-59-9Relevant articles and documents
Synthesis of eosinophil infiltration inhibitors with antihistaminic activity.
Gyoten, Michiyo,Nagaya, Hideaki,Fukuda, Shigeru,Ashida, Yasuko,Kawano, Yasuhiko
, p. 122 - 133 (2007/10/03)
A series of [1, 2, 4]triazolo[1, 5-b]pyridazines (5) and imidazo[1, 2-b]pyridazines (6) having cyclic amines was synthesized and evaluated for antihistaminic activity and inhibitory effect on eosinophil infiltration. When a piperidine or a piperazine containing a benzhydryl group and a suitable spacer was incorporated at the 6-position, the fused pyridazines were found to exhibit both antihistaminic activity and an inhibitory effect on eosinophil chemotaxis. Above all, 6a showed potent antihistaminic activity, but little blockade of central H(1) receptors in contrast with its complete blockade of peripheral H(1) receptors as determined by an ex vivo binding assay. Furthermore, 6a inhibited eosinophil infiltration of the skin caused by a topical antigen challenge in sensitized guinea pigs, while an antihistamine terfenadine was not effective. After the pharmacokinetic study, 6a was found to be rapidly hydrolyzed to 6o, which was also orally active. Compound 6o, 2-[6-[[3-[4-(diphenylmethoxy)piperidino]propyl]amino]imidazo[1, 2-b]pyridazin-2-yl]-2-methylpropionic acid dihydrate (TAK-427), having both antihistaminic and antiinflammatory activity, is currently undergoing clinical trials as a therapeutic agent for atopic dermatitis and allergic rhinitis.